CB Scientific, Inc. (OTC PINK:CBSC) has officially rebranded as Cardiac Biotech Solutions, Inc., marking a strategic shift to better align with its core mission in cardiac health technology. The name change, which became effective May 7, 2025, follows approval from both the Financial Industry Regulatory Authority (FINRA) and company shareholders at their March 14, 2024 annual meeting.
The company will retain its CBSC ticker symbol and current CUSIP number despite the corporate rebranding.
Strategic Rebranding Reflects Core Mission
"We believe the name Cardiac Biotech Solutions more accurately reflects our core mission of advancing heart health," explained Charles Martin, Chief Executive Officer of CBSC. The rebranding coincides with significant product developments, particularly the successful FDA clearance of the company's next-generation cardiac monitoring technology.
The timing of this corporate identity shift aligns with the company's expanding global footprint in non-invasive cardiac monitoring solutions, as it prepares to serve multiple international markets.
MyCardia AT Monitor Launches with Enhanced Features
The company has officially launched its next-generation MyCardia AT cardiac event monitor, developed in collaboration with Datrix, LLC. The FDA-cleared device represents a significant advancement in remote cardiac monitoring technology.
The MyCardia AT monitor features:
- Lightweight, easy-to-wear design for improved patient compliance
- Flexible options for transmitting cardiac event recordings
- Seamless integration with the AWS Cloud-based MyCardia portal
- Compatibility with MyCardia mobile applications across iOS and Android platforms
- Support for Apple, Google, and WeChat platforms globally
This advanced monitoring system enables physicians to detect and diagnose transient cardiac arrhythmias more effectively, addressing a critical need in cardiac care. The technology's design prioritizes both clinical utility and patient experience, potentially improving compliance rates for at-risk patients.
Global Expansion Underway
Cardiac Biotech Solutions is executing a phased international rollout strategy for the MyCardia AT monitor:
- Initial deployment across Southeast Asia, Hong Kong, and Macau is already in progress
- Regulatory submission process has resumed in China in partnership with Shenzhen Pump and representatives from the National Medical Products Administration (NMPA)
- Canadian market entry has begun through distribution partner Your Heart Protector Corp.
This expansion strategy leverages established international distribution partnerships to accelerate market penetration across diverse healthcare systems.
Leadership and Corporate Changes
In addition to the rebranding and product launch, the company has made significant leadership changes. William "Trip" Thomas, a licensed CPA with extensive experience in financial reporting and regulatory compliance, has been appointed Chief Financial Officer, succeeding Brooke Turk.
The company has also voluntarily delisted from the OTCQB Venture Market to preserve capital for future business growth, though its common shares continue trading on the OTC Pink Open Market.
Technology Integration and User Experience
A key differentiator for the MyCardia AT system is its comprehensive integration across multiple technology platforms. The cardiac event monitor works in conjunction with cloud-based acquisition software and smartphone applications, creating a seamless ecosystem for both patients and healthcare providers.
The system's architecture enables improved monitoring compliance for patients at risk of abnormal heart rhythms while providing physicians with more accurate diagnostic information. This integrated approach addresses both clinical needs and user experience considerations across the care continuum.
As Cardiac Biotech Solutions continues its evolution and expansion, the company has committed to providing timely updates through press releases and regulatory filings to keep shareholders, industry participants, and markets informed of new developments.
